HI
CPRX

HBK Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

HBK Investments’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.6M Buy
+2,820,302
New +$83.2M 0.87% 25

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM

HBK Investments's CPRX Position: Q2 2026 in Review

HBK Investments opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 2,820,302 shares worth $88.6M. The stake represents 0.87% of the portfolio and ranks #25 among its holdings.

370 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • HBK Investments held 2,820,302 shares of Catalyst Pharmaceutical worth $88.6M as of Q2 2026.
  • Catalyst Pharmaceutical was a new HBK Investments position in Q2 2026.
  • Catalyst Pharmaceutical made up 0.87% of HBK Investments's portfolio in Q2 2026, its #25 holding.
  • 370 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on HBK Investments's 13F filing for Q2 2026, filed 14 Aug 2026.